Michela Gastaldi

ADDAX was founded after extensive research by its founders on the fixation of pathological tissues, with the goal of eradicating Formalin—a water solution based on formaldehyde, a carcinogenic and mutagenic substance—from hospitals, research centers, and laboratories. Despite its risks, Formalin is still widely used due to the lack of valid and safe alternatives. To address this, ADDAX developed and patented GAF® (Glyoxal Acid Free), an innovative, non-toxic fixative that provides comparable or superior efficiency to Formalin across all applications. GAF® ensures diagnostic accuracy while protecting healthcare professionals from work-related diseases and cancers. In addition to its health benefits, GAF® offers a solution with a significant positive environmental impact. By eliminating the use of Formalin, it reduces the production of hazardous waste and limits the environmental impact associated with its disposal. Furthermore, GAF® activates a chain of positive factors within the framework of a circular economy, creating a virtuous cycle of savings and efficiency: Emission treatment systems: GAF® eliminates the need for costly air filtration and enhanced ventilation systems, reducing installation and maintenance expenses., Air quality monitoring: Organizations using GAF® can significantly lower the costs and frequency of inspections and workplace air quality monitoring., Employee health surveillance and training: GAF® minimizes health risks, simplifying the requirements for specialized training and health monitoring programs., Disposal of hazardous waste: GAF® facilitates less complex and more cost-effective waste management, reducing the burden of disposing of toxic and carcinogenic substances. GAF®, a patented, CE-marked, and FDA-approved product, represents a paradigm shift toward safer, more sustainable, and environmentally friendly practices, benefiting public health and economic sustainability.